

WORLD ALZHEIMER'S DAY

Landmarks in Alzheimer's Disease (AD)

1906

AD was named after Alois Alzheimer after he described the symptoms of a patient known as Auguste D

- Amyloid plaques and neurofibrillary tangles described

Oskar Fischer reported neuritic plaques in 12 of 16 cases of senile dementia in 1907



1968

First measurement scale for assessing cognitive and functional decline



1976

AD as the most common form of dementia.

Cholinergic hypothesis of AD



1982

Innate immune system implicated in AD



1984

Identifying beta-amyloid

Peptide sequence of beta-amyloid established



1985

The First International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD™. (Eilat)



1986

Tau protein as a key component of tangles



1987

APP cloned and sequenced, Aβ42 and 43 fragments identified



1988

Tau cloned

The first International Springfield meeting on AD that became now AAT-ADPD focus meeting

The first international AD conference that became ICAD and now AAIC



1990


Cognitive impairment correlates with synaptic damage

APP Dutch mutation



1991

APP London mutation



1992

Amyloid hypothesis marks conceptual shift from descriptive to mechanistic view

APP Swedish Mutation



1993

ApoE4 major risk factor for late-onset AD



1994

The first World Alzheimer's Day (WAD) launches on September 21



1995

Mutations in presenilin-1 and presenilin-2 cause autosomal-dominant AD

Tacrine: the first drug approved for AD



1996

Donepezil approved

Alzheimer Research Forum was founded



1997

Rivastigmine approved

Lysosomal degradation impaired early on in AD



1998

CSF Aβ, CSF Aβ/tau ratio predict decline in cognitively normal elderly

and FAD mutation carriers



1999

BACE1 cloned and identified as β-secretase

First Aβ active immunotherapy in mice

Plaque, tangle pathology begin more than decade before symptoms, represent 'preclinical' AD



2000

Galantamine approved



2001

Volumetric MRI broadly developed as marker of change over time in sporadic and familial AD



2002

Dendritic tau mediates Aβ-induced synaptic toxicity, circuit abnormalities


Memantine approved



2003

Reactive astrocytes crowd near plaques, degrade Aβ

Head injury increases risk



2004

Amyloid PET in human brain with PIB



2005

Obesity as a risk factor in AD



2006

Prion-like mechanisms for amyloid toxicity



2007

The first CTAD meeting on AD



2008

Dominantly Inherited AD Network



2009

AD prevention Initiative

Successive biomarker changes in AD



2010

Plaques precede prevalence of AD dementia



2011

Tau found in vivo in brain interstitial fluid



2012

TREM 2 mutation in FTD and AD

Icelandic APP mutation protects against AD

Florbetapir approved by the FDA



2013

G8 Dementia Summit



2015

The 12th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders.

(Nice) First clinical results with Aducanumab in AD



2016


About 80 therapeutics in clinical trials in AD



2017

The 13th International Conference on Alzheimer's and Parkinson's Diseases & related neurological disorders

AD/PD™ (Vienna)



2018

AAT-ADPD Focus Meeting (Torino)

